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1. Introduction 
Blood glucose homeostasis is controlled by the endocrine cells of the pancreas,  located in 
the islets of Langerhans. The islet cells monitor the concentration of glucose in the blood and 
secrete hormones with opposite effects. When after a meal the blood glucose concentration is 
increasing, the beta cells, which are the most numerous islet cells, secrete the hormone 
insulin to reduce blood glucose. Insulin stimulates the uptake of glucose by cells of the body 
and stimulates the conversion of glucose to glycogen in the liver. If the glucose level falls too 
far, islet alpha cells secrete the hormone glucagon, which stimulates the breakdown of 
glycogen to glucose in the liver and therefore increases blood glucose between meals. 
Optimal control of blood glucose levels depends on delicate changes in insulin production 
and secretion by the pancreatic beta cells and on their capacity for a large increase of 
secretion after meals, requiring large stores of insulin [1]. Very important is the need for the 
beta-cell mass to be closely regulated by glucose and hormonal effects on beta-cell 
replication, size, apoptotic elimination and, under certain conditions, neogenesis from 
progenitor cells. Failure to adapt to changes in body mass, pregnancy, insulin sensitivity of 
peripheral tissues, or tissue injury may lead to the development of chronically elevated 
blood glucose, or diabetes [2]. The increasing global prevalence of diabetes  has stimulated 
efforts to develop new therapeutic strategies like beta-cell replacement or regenerative 
medicine. The existing therapies with exogenous insulin or hypoglycemic agents for type 1 
and type 2 diabetes are unsatisfactory, since they do not offer a cure and are mostly 
insufficient for preventing the secondary complications associated with diabetes [3]. 
Despite an enormous increase in our understanding of islet differentiation and 
development, there is sparse information regarding the factors and pathways that regulate 
growth, survival, and death of islet cells. The number of islet beta cells present at birth is 
mainly generated by the proliferation and differentiation of pancreatic progenitor cells, a 
process called neogenesis. Shortly after birth, beta-cell neogenesis stops and a small 
proportion of cycling beta cells can still expand the cell number  to compensate for increased 
insulin demands, albeit at a slow rate. The low capacity for self-replication in the adult is too 
limited to result in a significant regeneration following extensive tissue injury. Likewise, 
chronically increased metabolic demands can lead to beta-cell failure to compensate. 
Neogenesis from progenitor cells inside or outside islets represents a more potent 
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mechanism leading to robust expansion of the beta-cell mass, but it may require external 
stimuli. For therapeutic purposes, advantage could be taken from the surprising 
differentiation plasticity of adult pancreatic cells and possibly also from stem cells. Recently 
a large number of factors controlling the differentiation of beta-cells has  been identified. 
They are classified into the following main categories: growth factors, cytokine and 
inflammatory factors, and hormones such as PTHrP and GLP-1[4,5]. In general , treatment  
with these external stimuli can restore a functional beta-cell mass in diabetic animals, but 
further studies are required before it can be applied to humans. 
2. Parathyroid hormone-related peptide 
PTH-related peptide (PTHrP) was first discovered as the most frequent cause of the syndrome 
of humoral hypercalcemia of malignancy [6-10]. However, PTHrP mRNA is widely expressed 
under normal conditions, and gene ablation experiments have established that this peptide 
plays an essential role in normal skeletal development [11]. Human PTHrP can be produced as 
a 141-amino acid peptide or, through alternative mRNA splicing, as a protein comprising 
either 139 or 173 amino acids. PTHrP binds to the same receptor as PTH, and the biological 
responses elicited by either ligand through this common PTH1R-receptor are largely 
indistinguishable, at least with regard to mineral ion homeostasis [12-15]. For these actions of 
PTH and PTHrP, the amino-terminal (1–34) peptide fragments are sufficient, as PTH-(1–34) 
and PTHrP-(1–34) display both  high-affinity receptor binding and efficient receptor activation. 
There is a growing body of evidence, however, suggesting that the midregional and/or 
carboxy-terminal fragments of either peptide, derived through posttranslational processing 
mechanisms, also have biological activity [16-18]. However, the observed activities of 
midregional and COOH-terminal fragments of PTH and PTHrP are unlikely to be related to 
adult mineral ion homeostasis and are probably mediated through receptors that are distinct 
from the PTH1R, although these receptors have not yet been identified. 
3. Structure-activity relations in PTH and PTHRP 
PTH and PTHrP show significant sequence homology within the first 13 amino acid 
residues (Fig1), and this sequence conservation reflects the functional importance of the 
amino-terminal residues in receptor signaling [19- 21]. Between PTH and PTHrP, sequence 
homology decreases markedly in the 14–34 region, where only three amino acids are 
identical, and beyond residue 34 there is no recognizable similarity. 
For both PTH and PTHrP, the 15–34 region functions as the principal PTH1R binding 
domain, and these portions of the two peptides probably interact with overlapping regions 
of the receptor, as the two fragments compete equally for binding with radiolabeled PTH-
(1–34) or PTHrP-(1–36) to the PTH1R [22,23].These findings  also suggest that the two 
divergent receptor binding domains of PTH and PTHrP adapt similar conformations. 
The three-dimensional crystal structures of PTH or PTHrP are not known, but the peptides 
have been  analyzed extensively by nuclear magnetic resonance (NMR) spectroscopic 
methods. In general, these studies indicate that, under certain solvent conditions, PTH-(1–
34) and PTHrP-(1–36) analogs contain defined segments of secondary structure, including a 
relatively stable a-helix in the carboxy-terminal receptor-binding domain, a shorter less 
stable helix near the aminoterminal activation domain, and a flexible hinge or bend region 
connecting the two domains [24-26]. 
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Fig. 1. Parathyroid hormone (PTH) and PTH-related peptide (PTHrP) and analogs: 
functional domains and receptor selectivity determinants. A: amino acid sequences of the 
bioactive (1–34) regions of native human PTH and human PTHrP. In the schematic of 
human PTHrP, only residues that differ from human PTH are provided, and amino acids 
that are identical to the corresponding residues of PTH are represented by open circles. Bars 
represent peptide fragments that exhibit weak receptor binding (15–34) or antagonist and 
inverse agonist properties (7–34)  
Although most NMR solution studies find evidence for peptide flexibility, the question of 
whether the conformations of PTH and PTHrP recognized by the receptor are folded with 
tertiary interactions, as suggested by some studies [27-29], or extended, as suggested by 
other analyses , remains unanswered. 
4. Receptors for PTH and PTHRP 
As indicated above, PTH and PTHrP mediate their actions primarily through the PTH1R 
PTH/PTHrP receptor, a G protein-coupled receptor (GPCR) with seven membrane-
spanning helices[30]. The PTH1R forms, along with the receptors for secretin, calcitonin, 
glucagon, and several other peptide hormones, a distinct family of GPCRs that exhibit 
none of the amino acid sequence motifs found in the other subgroups of the superfamily 
of heptahelical receptors [31-32]. These peptide hormone receptors, called class II or 
family B receptors [31], can be distinguished from other GPCRs by their large,  (150 
amino acid) amino-terminal extracellular domain containing six conserved cysteine 
residues, as well as by several other conserved amino acids that are dispersed 
throughout the NH2-terminal domain, the membrane-embedded helixes, and the 
connecting loops. 
Significant progress has been made in understanding the role of the common PTH/PTHrP 
receptor, the PTH1R, in mammalian biology, particularly with regard to its normal role in 
chondrocyte growth and development, and its pathological role in two rare genetic 
disorders in humans. Amino acid residues in the PTH1R and PTH2R that are likely to be 
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important for ligand-receptor interaction and for signal transduction have been identified 
through mutagenesis methods and through photoaffinity cross-linking techniques. 
Although these studies have provided new insights into the mode of ligand-receptor 
interaction, there is still much that needs to be learned about this complex process. 
5. Pancreas development 
The pancreas originates from the foregut endoderm as ventral and dorsal buds, beginning at 
embryonic day (e) 9.5 in the mouse, and the two buds later fuse at approximately e12.5 [33]. 
The endodermal epithelium proliferates in response to various fibroblast growth factors 
(FGFs) produced by the adjacent mesenchyme [34], undergoes branching morphogenesis, 
and differentiates into ductal, exocrine, and endocrine cells. Evagination and development of 
the ventral pancreatic bud is slightly delayed compared with that of the dorsal bud, and the 
ventral bud gives rise to fewer endocrine cells than does the dorsal bud [35]. The ventral and 
dorsal buds also differ with regard to the signals they require for development.  
5.1 Dynamic changes in an organism’s ß-cell mass 
In addition to maintaining ß-cell mass under normal circumstances, as just discussed, an 
organism must also be able to alter its ß-cell mass in accordance with its requirements for 
insulin. In states of insulin resistance, such as pregnancy and obesity, ß-cell mass is known 
to increase [45]. Such ß-cell mass expansion is accomplished primarily by increasing ß-cell 
proliferation, although neogenesis may also contribute. However, when compensatory ß-cell 
mass expansion is inadequate, diabetes ensues – gestational diabetes in the case of 
pregnancy, and type II diabetes in the case of obesity. Although the majority of humans do 
not become diabetic in these circumstances, a significant portion of the population is 
predisposed to ß-cell failure, for currently unknown reasons. It is likely that factors that 
regulate ß-cell proliferation may play a role, although whether the factors that regulate ß-cell 
mass expansion are the same as those that regulate ß-cell mass maintenance is unclear.       
5.2 Regulatory factors of b-cell mass expansion and maintenance 
During pregnancy, rats exhibit a greater than 50% increase in ß-cell mass, which is 
accomplished primarily through an approximate threefold increase in ß-cell proliferation 
[46]. The chief stimuli of ß-cell proliferation during pregnancy are placental lactogens (PLs), 
although prolactin (Prl) and growth hormone (GH) also have similar effects on ß-cells and 
are also elevated during pregnancy. After delivery, ß-cell mass returns to normal levels 
within 10 days through increased ß-cell apoptosis, decreased ß-cell proliferation, and ß-cell 
atrophy.  
Diet-induced obesity results in insulin resistance and ß-cell mass expansion in humans and 
mice. The C57Bl/6 mouse strain is notoriously susceptible to these effects, exhibiting a 2.2-
fold increase in ß-cell mass and proliferation after 4 months on a high-fat diet versus a 
control diet [51]. However, these mice eventually become diabetic and lose their ß-cell mass 
due to increased ß-cell apoptosis and reduced ß-cell proliferation.  
In genetic models of obesity and insulin resistance, there is also a compensatory expansion 
of ß-cell mass. For example, db/db mice, which lack a functional leptin receptor, exhibit a 
twofold increase in ß-cell mass by 8 weeks of age [52]. This timepoint correlates with the 
onset of diabetes, which progresses from glucose intolerance that is first observed between 4 
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and 6 weeks of age. A similar rat model, the Zucker diabetic fatty (ZDF) rat (fa/fa), also has a 
homozygous mutation in the gene encoding the leptin receptor. ZDF rats exhibit increased 
ß-cell mass and increased ß-cell proliferation prior to the onset of diabetes, but increased ß-
cell apoptosis prevents them from adequately expanding their ß-cell mass after the onset of 
diabetes, despite continued high rates of ß-cell proliferation [53]. This phenotype contrasts 
with what is observed in non-diabetic Zucker fatty (ZF) rats, which possess the same 
mutation as ZDF rats and also become obese and insulin resistant but do not develop 
diabetes due to sufficient ß-cell mass expansion through increased ß-cell proliferation, 
neogenesis, and hypertrophy [53].  
Another model of insufficient ß-cell mass expansion is the insulin receptor substrate two 
null mouse [Irs2–/–; 54]. Global inactivation of Irs2 results in severe insulin resistance, both 
centrally in the brain causing obesity, and peripherally, for which ß-cell mass expansion 
should be able to compensate. However, because ß-cells require Irs2 for proper proliferation 
and function, Irs2–/–mice are unable to expand their ß-cell mass, and they develop diabetes 
by 10 weeks of age. This phenotype is not observed in Irs1–/–mice, despite the fact that these 
mice exhibit similar insulin resistance, because Irs1 is not required for ß-cell mass expansion. 
These experiments provide additional evidence that Irs2 is required for ß-cell mass 
expansion in response to insulin resistance. Furthermore, overexpression of Irs2 in ß-cells 
(Rip-Irs2) is sufficient to prevent ß-cell failure in diet-induced obesity and streptozotocin-
induced diabetic models [55].  
6. The role of PTHrP in diabetes 
PTHrP was discovered in the early 1980s as the factor responsible for humoral 
hypercalcemia of malignancy. Subsequent studies found PTHrP expression to be 
widespread in almost all tissues and organs of the body. One such tissue is the islet of 
Langerhans, in which all four endocrine cell types (α, ß, Ǆ and ǅ pancreatic polypeptide 
cells) produce PTHrP. Not only is the peptide made in islets, but receptors for PTHrP also 
seem to be present on ß cells. To begin to evaluate the possible role of PTHrP in pancreatic 
islets,  transgenic mice overexpressing PTHrP in the ß cells of islets were developed  using 
the rat insulin II promoter (RIP). These RIP-PTHrP mice displayed islet cell hyperplasia, 
significant hypoglycemia under both fasting and nonfasting conditions, as well as 
inappropriate hyperinsulinemia. Insulin expression was shown to be up-regulated both at 
the messenger RNA and protein level in whole pancreas of RIP-PTHrP mice. [58] 
PTHrP is a prohormone that is posttranslationally endoproteolytically cleaved to yield a 
family of mature secretory peptides [58-60] . These include an amino-terminal secretory 
form, which binds to and activates the recently cloned parathyroid hormone receptor [10] , 
as well as several other mid-region, and carboxyl-terminal secretory forms of the peptide. 
Since the full-length PTHrP(1-141) cDNA was used to construct the transgene, these 
experiments do not provide information regarding which of the several secretory forms is 
(or are) responsible for the hyperinsulinemia and islet hyperplasia observed. 
The phenotype does not seem to result from a developmental effect of PTHrP on the 
pancreas, because transgenic mice at 1 week of age were normoglycemic and displayed 
normal islet mass despite expression of the PTHrP transgene. In contrast, a visible increase 
in islet mass (2-fold) was observed in RIP-PTHrP mice by 12 weeks of age, and increased 
further (3- to 4-fold) by 1 yr of age. Both an increase in the number of ß cells per islet as well 
as an increase in total islet number contribute to the enhancement of islet mass in these mice. 
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The increase in islet mass in RIP-PTHrP transgenic mice does not seem to be a result of an 
increase in the proliferation rates of preexisting ß cells of the islet. Thus, the increased islet 
mass in RIP-PTHrP mice most likely results from a decrease in the normal rate of ß-cell 
turnover or apoptosis and/or enhanced neogenesis(62). In other cell types like 
chondrocytes, neuronal cells, and prostate carcinoma cells, PTHrP has been shown to have 
an antiapoptotic or protective effect against cell death. In line with this, ß cells of the RIP-
PTHrP mice have also been shown to be more resistant to the cytotoxic effects of high doses 
of the diabetogenic agent streptozotocin (STZ): RIP-PTHrP transgenic mice remain relatively 
euglycemic unlike their normal littermates, which become severely diabetic following STZ 
injection. Histologically, the resistance to the diabetogenic effects of STZ seems to result, at 
least partially, from PTHrP-induced resistance to STZ-mediated ß-cell death (63).  
Another surprising feature of the RIP-PTHrP mouse is that despite impressive 
overproduction of PTHrP, systemic hypersecretion of PTHrP does not occur and 
hypercalcemia does not develop. This is surprising because PTHrP is clearly sorted into the 
regulated secretory pathway [64-67], and is copackaged with insulin in islet cells [66], and is 
secreted in response to insulin secretagogues [66]. This may reflect clearance of PTHrP by 
the liver after it is secreted into the portal circulation. 
These findings suggest that PTHrP may have potential in  therapeutic strategies designed to 
increase ß-cell mass and function. Specifically, this peptide could prove to be valuable in 
improving islet transplant survival in type 1 diabetes. 
Recently, the discovery of a family of islet homeobox genes including 
PDX1/STF1/IPF1/IDX1, ISL1, PAX-4, PAX-6, NeuroD/ß-2 and others [74-77] and putative 
islet growth factors such as GH, PRL, placental lactogen, hepatocyte growth factor, the reg 
family of proteins, and the recently identified protein, INGAP [78-80] has focused attention 
on the mechanisms responsible for pancreatic and islet development and on the 
mechanisms whereby islet neogenesis occurs in states of islet injury, subtotal 
pancreatectomy, or pregnancy, and whereby normal islet mass is sustained throughout life. 
If PTHrP does not have an obvious role in islet cell proliferation or in apoptosis of existing 
islets but is nevertheless very potent in increasing islet mass, it is possible that PTHrP may 
play a role in normal islet neogenesis or in differentiation from uncommitted precursor cells, 
such as ductular epithelial cells. In this regard, it has been reported that PTHrP is indeed 
expressed in pancreatic ductular cells [81]. 
For attaining a well-functioning ß-cell mass, PTHrP is a very promising candidate among 
insulinotropic peptides including hepatocyte growth factor, GLP-1, and exendin-4 [82]. 
Indeed, rat insulin gene–promoted overexpression of PTHrP in mouse islets presented a 
twofold increase in total islet number and total islet mass, as well as in insulin content [83]. 
In contrast, transgenic mice expressing exendin-4, a long-acting GLP-1–like peptide, 
presented no remarkable change in total islet number and total islet mass [84]. Thus, PTHrP 
seems to be potent in upholding a well-functioning ß-cell mass.  
7. Preleminary clinical observations 
As had been the case in so many other tissues, the observation of physiological and 
pathophysiological responses to PTH was documented in the islet and in insulin target 
tissues long before the discovery of PTHrP. The significance of these observations was 
difficult to fathom at the time, since no obvious physiological link between calcium 
homeostasis and glucose metabolism readily suggested itself. For example, it had long 
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been observed that glucose intolerance and frank diabetes occurred in association with 
hyperparathyroidism more often than would be expected by random coincidence [85]. It 
also had been shown that the elevated PTH concentrations in patients with primary 
hyperparathyroidism induced both mild peripheral insulin resistance and augmented 
insulin response to hyperglycemia. In the majority of reports, the data on insulin response 
are difficult to interpret because of the effects on insulin secretion of the hypercalcemia 
that accompany the elevated circulating PTH concentrations in patients with 
hyperparathyroidism. In one study, however, normal volunteers made hypercalcemic by 
PTH injection over 8 days demonstrated augmented insulin responses to glucose and to 
intravenous tolbutamide, while a control group rendered similarly hypercalcemic by 
calcium infusion failed to demonstrate an augmented insulin response to glucose [86]. To 
investigate the direct effects of PTH on pancreatic islets in vitro, Fadda et al. [87], before 
the description of PTHrP as an islet peptide,examined insulin secreation from isolated 
pancreatic islets in response to PTH-(1-34) and PTH- (l-84). These studies showed that 
PTH augmented both the first and second phases of secretion in response to 16.7 mM 
glucose. 
The suggested link between parathyroid gland function and the pancreatic islet was met, 
quite appropriately, with skepticism and for two reasons. First, as noted above, it was very 
difficult to envision a physiological scenario in which PTH could be construed as 
participating in normal islet regulation. Second, studies such as that reported by Fadda et al. 
[87] generally required concentrations of PTH far in excess of those encountered in 
hyperparathyroidism to observe an effect. One was therefore forced to conclude either that 
these effects were nonphysiological and therefore meaningless or to postulate that there is 
another natural peptide of physiological import within the islet that might be mediating 
these effects in the islet. At the time these studies were performed, no such normal islet 
product was known. As is now obvious, islet derived PTHrP is a candidate worthy of 
consideration. 
In 1992,Ishida et al,[88] reported that type 2 diabetics presented higher serum PTHrP 
levels than control subjects. However, in that study  no stimulation tests were done to 
demonstrate whether PTHrP is released from the pancreas in response to insulin 
secretagogues like glucose or calcium. Extensive studies have demonstrated that an 
increase in the cytosolic calcium is essential for glucose-stimulated insulin release[89]. 
Indeed, one of the mature, secretory forms of PTHrP, called mid-region PTHrP,was 
demonstrated by Wu et. al. [90] to increase cytosolic calcium levels in a pancreatic b cell 
line. Increased cytosolic calcium levels have also been reported in insulinoma cells, 
supporting the notion that PTHrP is not only secreted by pancreatic cells, but might also 
play an autocrine or paracrine role within the islets themselves[91].In 2006,Shor et al [92] 
examined the effects of two stimulatory secretagogues -glucose and calcium-after  an oral 
glucose load (75gr) to healthy controls. They reported that PTHrP and insulin rose in 
parallel although this response was not observed during the calcium load. Moreover , 
they found significant differences in basal serum PTHrP levels particularly in type 2 
versus type 1 diabetics and healthy controls. Ishida et al[88], proposed that elevated 
PTHrP levels might play a compensatory role in calcium homeostasis in diabetic patients. 
They speculate that these patients often exhibit osteopenia and lower than normal PTH 
levels with a net result the preservation of normal serum calcium levels. 
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Performing PTHrP serum determinations in a fasting state in type 2 diabetics by our group 
[93] we have found that PTHrP  was  statistically significant correlated with glucose in type 
2 diabetes (r:0,992-p<0,0001)  and in normal subjects in the fasting state (r:0,908-p<0,0001). 
Additionally, PTHrP serum levels exhibited a significant increase in type 2 diabetes 
compared to control subjects (Diabetics-PTHrP(Median):380 pg/ml versus Normals-
PTHrP(Median):180 pg/ml , p<0,001). Interestingly, PTHrP showed a positive correlation 
with insulin levels only among healthy individuals presumably due to defective glucose 
stimulated insulin secretion known to occur in type 2 diabetics. 
In  conclusion ,the recognition  that PTHrP-a protein mostly indentified as a tumor product 
in cases of humoral malignant hypercalcemia, is found in almost every body tissue 
including the pancreas , where it is processed into multiple secreatory forms,co-packed with 
insulin , and secreted in a regulatory fashion in response to insulin secretagogeus , opens 
new directions in the autocrine/paracrine role of PTHrP in the islets of Langerhans and 
raises several questions for further experimentation in both type 1 and type 2 diabetes. 
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